Introduction
============

Since its first discovery in 1981, Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS) has killed more than 25 million people worldwide and is today the major threat to human health. However, due to the introduction of highly active antiretroviral therapy (HAART) as well as the impact of preventive measures, the prevalence and incidence of HIV have declined globally over the last decade except for parts of Eastern Europe and Central Asia where a slight increase has been observed ([@B157]; [@B25]; [@B44]; [@B80]; [@B143]). Even though HAART provides stable viral suppression, it is not devoid of undesirable side effects, especially in persons undergoing long-term treatment. The present therapy finds its limitations in the emergence of multidrug resistance and accordingly finding new drugs and novel targets is the need of the hour to treat the infected persons and further to attack HIV reservoirs in the body like brain, lymph nodes to achieve the ultimate goal of complete eradication of HIV and AIDS ([@B161]; [@B23]). Nature has always been considered a basis for providing resources that can be used to fight off infections and treat diseases. Among these resources there have been findings of medicinal plants that have anti-HIV properties with low levels of toxicity. For the management of HIV/AIDS, in 1989 the World Health Organization (WHO) had declared the necessity to assess ethnomedicines and other natural products. To quote: "In this context, there is need to evaluate those elements of traditional medicine, particularly medicinal plants and other natural products that might yield effective and affordable therapeutic agents. This will require a systematic approach" ([@B172],[@B173]). Moreover, because they are fairly not as expensive and have less side effects, phytomedicines are retrieving patient approval ([@B161]; [@B149]). Medicinal effects of plants incline to stabilize physiological function and fix the fundamental cause of the condition ([@B110]). Recently, there has been a sustained bio prospective effort to isolate the active leads from plants and other natural products for treatment of HIV and management of AIDS ([@B9]; [@B161]) and also screening of plants based on ethnopharmacological data enhances the ability of discovering novel anti-HIV compounds ([@B40]; [@B41]). Indigenous knowledge of medicinal plants further provides leads toward therapeutic concept, thereby accelerating drug discovery. Thus, it is essential to explore for new antiretroviral agents which can be combined with or substitute the present resource of drugs against HIV ([@B76]).

Also, due to the widespread infection of HIV there has been a determination for the discovery and use of medicinal agents that can inhibit the virus. HIV type-1 (HIV-1) displays extraordinary genetic variation and can be phylogenetically classified into three distinct groups and several subgroups (A--K) across the globe. While HIV-1 clade C dominates the HIV-1 epidemic worldwide with more than 50% of the total viral infections, predominantly in Southern Africa, India, and other parts of Asia, HIV-1 subtype B is mainly found in (Western) Europe and in the Americas, accounting for about 10% of the total infections ([@B126]; [@B59]; [@B158]; [@B58]; [@B127]). In places like Brazil, clade C viruses have been spreading rapidly to replace the previously dominant clade B epidemic ([@B17]; [@B46]; [@B31]). The virus basically utilizes the host's cellular machinery for its own replication leading to extensive viral and host interactions during its life cycle ([@B75]; [@B83]; [@B160]; [@B4]; [@B128]; [@B16]; [@B45]). Some of the cellular factors aid replication while others are inhibitory ([@B12]; [@B107]; [@B13]; [@B123]; [@B8]; [@B141]). All these mechanisms lead to chronic immune activation, the key factor in HIV-1 immunopathogenesis. The disease progression ([@B24]; [@B131]; [@B144]; [@B170]) is associated with the gradual T lymphocyte decline, first taking toll of helper CD4^+^ T cells and then the cytotoxic CD8^+^ T cells. The pronounced decline of CD4^+^ T cells occurs due to the destruction of both infected and uninfected cells mainly because of apoptosis of activated cells, diminished hematopoiesis and thymic maturation. Apart from inducing immune dysfunction, HIV-1 infection affects neuronal function by significantly increasing several cellular proteins in the brain, including amyloid precursor protein (APP), especially in the axons present in the subcortical white matter tracts ([@B38]; [@B51]; [@B151]). During HAART therapy HIV persists in the brain and local inflammatory responses to the virus can lead to higher APP production and β-amyloid deposition which may lead to the progression of Alzheimer's disease and HAND ([@B48]). Accordingly, finding new drugs and novel targets is the need of the hour to treat the infected persons and further to attack HIV reservoirs in the brain to achieve the ultimate goal of complete eradication of HIV and AIDS.

Extensive attention has been given to the pathogenesis of HIV-1 infection and associated immunologic mechanisms, however, the basic challenge that still persists is to develop viral replication-targeted therapy using novel anti-HIV compounds with new mode of action, accepted toxicity, and less resistance profile. Accordingly, in this review, plant substances showing a promising anti-HIV activity and HAND will be summarized along with the targets they interact including the specific objectives for the pursuit of plants and other natural products with identified active substances and mechanisms as well as those with unidentified active mechanisms against HIV, AIDS, and other neurocognitive disorders.

HIV-Associated Neurocognitive Disorders (HAND) and Antiretroviral Therapy (ART)
===============================================================================

Individuals infected with HIV have conditions of fluctuating degrees of impairment of cognition and associated functioning and can develop HIV-associated neurocognitive disorders (HAND; [@B7]). Invasion and replication of HIV in the brain parenchyma is accomplished by brain perivascular macrophages, endogenous microglia, and some astrocytes that are infected and can initiate the neuropathogenesis of HAND ([@B69]; [@B101]). Immune activation of resident glia and neuroinflammation are associated with this infection and neuronal injury. The general occurrence of HAND and related diseases continue to be at high levels even with the extensive use of antiretroviral therapy (ART) that has radically reduced the occurrence of the severest form of HAND, HIV-associated dementia (HAD; [@B136]; [@B100]; [@B114]; [@B55]). The persistence of this high risk for HAND in individuals experiencing effective control of systemic HIV viral load is incompletely explained, and suggested factors include effects of aging on brain vulnerability, persistence of HIV replication in brain macrophages, evolution of highly neurovirulent CNS HIV strains, and even long-term CNS toxicity of ART ([@B55], [@B56]). The features linked with increasing the inflammatory setting within the CNS and HIV replication are what drive the pathogenesis of HAND. Neuronal damage associated with HAND can be augmented by subordinate effects of aging, movement of activated monocytes, systemic immune activation and drug abuse and can continue in spite of the effective systemic control of HIV replication by ART ([@B47]). Active complementary neuroprotectants are substances that can overturn systemic immune activation and associated inflammation both systemically and within the CNS ([@B71]; [@B77]; [@B52]; [@B101]). Drugs that aim toward these cellular pathways could quickly ease testing and application of possible complementary neuroprotective approaches against HAND. Prevention and treatment of HAND requires strategies aimed at suppressing CNS HIV replication and effects of systemic and CNS inflammation in aging and substance-abusing HIV populations. Use of improved CNS-penetrating ART must be accompanied by evaluation of potential ART neurotoxicity.

Factors and Neurotoxic Compounds Inducing HIV-Associated Neurocognitive Disorders
=================================================================================

After initial infection and seroconversion, HIV usually reaches the brain. Infected monocytes migrating across the blood--brain barrier (BBB), which can be seen as a "Trojan horse" mechanism, is one concept suggested for potential viral entrance. After these infected monocytes migrate across the endothelium, they settle as infected perivascular macrophages. It has been proposed that the virus is spread by cell-to-cell interaction between microglia cells and macrophages ([@B70]). The main cell types that upkeep viral replication in the brain are multinucleated giant cells (fused microglia cells and macrophages) and macrophages in the perivascular spaces ([@B50]). A multifaceted cascade is prompted within the brain with recurrent exposures and heightened viral replication within microglia. Inside the brain tissue is where viral proteins are released which stimulate astrocytes and microglia to produce cytokines, chemokines, and other inflammatory agents ([@B115]; [@B2]). Release of viral proteins is further stimulated by these cell-encoded indicators that support the increase of HIV replication in microglia cells. This can produce a toxic effect on neurons, causing neuronal dysfunction and neuronal loss. Nevertheless, when a collection of these factors are existing along with the HIV infection, a distinctive neuropathological signature is seen. Pathological alterations are usually minor with irregularities mostly taking place in basal ganglia, brain stem, central white matter, frontal cortices, thalamus, and eventually leading to HAND ([@B148]). There are studies exploring the associated risk factors for the neurocognitive disorders in HIV patients and found that in some but not in all studies, CD4 nadir count ([@B109]; [@B36]; [@B56]) and detectable HIV plasma viral load ([@B154]; [@B19]; [@B32]), have been associated with neurocognitive impairment ([@B49]; [@B122]; [@B162]; [@B39]; [@B150]). Shortening in telomere length (TL), which has been used as a biomarker of aging, has also been reported in individuals with an HIV+ status ([@B182]; [@B96]; [@B121]). Also, shortened TL reported to increase the neurocognitive impairment and risk of dementia in non-HIV populations ([@B164]; [@B119]; [@B61]) which can be a marker for atypical age-related cognitive decline ([@B98]; [@B159]; [@B178]).

Naturally Derived Anti-HIV Agents
=================================

The following natural products namely Calanolides (Coumarins), Betulinic acid (a Triterpene), Baicalin (a Flavonoid), Polycitone A (an Alkaloid), Lithospermic acid (a Polyphenolic) can be mentioned as promising for anti-HIV agents (**Figure [1](#F1){ref-type="fig"}**) whereas Withanolides (Steroidal lactones; **Figure [2](#F2){ref-type="fig"}**) for HIV-associated neurocognitive disorders.

![**Structural formulae of representative anti-HIV natural products**.](fmicb-06-01444-g001){#F1}

![**Chemical structure of Withanolide A.** \[Reproduced with permission from [@B82].\]](fmicb-06-01444-g002){#F2}

Coumarins
---------

An example of non-nucleoside specific reverse transcriptase inhibitors (NNRTI) of the virus are calanolides which are a type of coumarin derived from different tropical tree species of the *Calophyllum* (Clusiaceae family; [@B33]). Calanolide A (**Figure [1](#F1){ref-type="fig"}**), ([@B163]), Calanolide B and its derivative 7,8-dihydrocalanolide B can prevent cytopathogenic effects of HIV-1 on host cells and are attained from the *Calophyllum lanigerum.* Cordatolide A and B are similar in structure to Calanolides and can inhibit replication of HIV-1. These compounds are extracted from the *Calophyllum cordato-oblongum* ([@B84]). Suksdorfin ([@B181]) is another compound that also has inhibitory effects on replication of the virus in the T cell line and is a pyrocoumarin derivative that can be extracted from the *Angelica morii* and *Lomatium suksdorfii* fruits from the Apiaceae family ([@B183]).

Terpenes
--------

Antiretroviral activity with diverse mechanisms of action have been observed with some triterpenoids. Betulinic acid (**Figure [1](#F1){ref-type="fig"}**), platanic and oleanolic acid tested in H9 lymphocyte cells have shown inhibition of HIV and can be obtained from the leaves of *Syzigium claviflorum* ([@B104]). Inhibition of HIV-1 replication in these cells were observed with oleanolic acid which can be attained from methanolic extract of the *Xanthoceras sorbifolia*, wood from the Sapindaceae family ([@B68]). Potent inhibitory activity against HIV-1 protease has been seen with maslinic acid derived from the *Geum japonicum* ([@B176]). Anti-HIV replication activity in H9 cells is observed with Celasdin B that is derived from ethanolic extract of the *Celastrus hindsii* which is from the Celastraceae family ([@B180]). The protostanes, garcisaterpenes A and C can suppress HIV-1 RTase activity and are obtained from the ethyl acetate extract of the stems and bark of *Garcinia speciosa* ([@B134]). Lanostane-type triterpene has also shown inhibition of HIV replication in H9 cells and is a suberosol obtained from ethanolic extract of the leaves and stems of *Polyalthia suberosa* from the Annonaceae family ([@B86]). Triterpene lactone, lancilactone C extracted from the roots and stems of *Kadsura lancilimba* is another compound that restrains HIV replication in these cells ([@B21]). The 12-*O*-tetradecanoylphorbol-13-acetate (TPA), a phorbol diester, can inhibit cytopathogenic effects of HIV-1 and is attained from methanolic extract of *Croton tiglium* from the Euphorbiaceae family. Prostratin, a phorbol ester also has anti-HIV properties and is extracted from *Homalanthus nutans* from the Euphorbiaceaen family ([@B37]).

Flavonoids
----------

Favorable anti-HIV activity have been exhibited by flavonoids and associated polyphenols. They are known for having antioxidant properties and have been found to show antiviral activity in different cell cultures ([@B118]). Baicalin (**Figure [1](#F1){ref-type="fig"}**) inhibits HIV replication in PBMC in a dose dependent fashion and is an anti-HIV flavonoid extracted from *Scutellaria baicalensis* ([@B117]). The 6,8-diprenylaromadendrin and 6,8-diprenylkaempferol, prenylated flavonoids, also show anti-HIV activity in the XTT-based, whole-cell screen and are derived from the extract of *Monotes africanus* ([@B103]). Flavonoid gallate ester and quercetin 3-*O*-(2-galloyl) *a*-[L]{.smallcaps}-arbinopyranose can inhibit integrase activity of HIV-1 and are obtained from ethanolic extract of *Acer okamotoanum* from the Aceraceae family ([@B72]). Hinokiflavone, robustaflavone, and biflavonoids have demonstrated inhibition of the polymerase of HIV-1 reverse transcriptase (RT) and are attained from methanolic extracts of leaves and twigs of *Rhus succedanea* from the Anacardiaceae family ([@B89]). Wikstrol B, a biflavonoid, also shows anti-HIV activity and can be isolated from extracts of roots of *Wikstroemia indica* from the Thymelaeaceae family ([@B62]). Xanthohumol, a prenylchalcone that has demonstrated inhibition of HIV-1 and is extracted from hops *Humulus lupulus* ([@B169]).

Alkaloids
---------

Different types of alkaloids have shown anti-HIV activity. One of the natural products with interesting activity on RT is polycitone A (**Figure [1](#F1){ref-type="fig"}**), an aromatic alkaloid isolated from the marine ascidian *Polycitor* sp. Polycitone A exhibits potent inhibitory activity on both RNA- and DNA-directed DNA polymerases ([@B92]). Papaverine, an alkaloid can inhibit HIV replication and is extracted from *Papaver sominiferum* from the Papaveraceae family. Buchapine is a type of quinolone that has shown inhibition of cytopathogenic effects of HIV-1 and is isolated from *Eodia roxburghiana* ([@B102]). Nitidine also shows anti-HIV activity and is extracted from the roots of *Toddalia asiatica* of the Rutaceae family ([@B153]). A piperidine flavone related alkaloid *O*-demethylbuchenavianine shows a hindrance to the activity of HIV and is attained from *Buchenavia capitata* of the Combretaceae family ([@B14]). Harmine has shown inhibition of HIV replication in H9 cells and is derived from *Symplocos setchuensis* ([@B63]). 1-Methoxy canthionone has anti-HIV properties and is obtained from *Leitneria floridana* ([@B175]). Hypoglaumine B, Troponine B, and Troponine A are sesquiterpene pyridine alkaloids that have shown to also possess anti-HIV properties and are isolated from *Tripterygium wilfordii* and *Tripterygium hypoglaucum* ([@B35]).

Phenolics
---------

Because of heightened phytohaemagglutinin-induced lymphocytes proliferation, prolonged administration of polyphenol-rich fruit juices is believed to be promising to HIV-positive individuals. There are several tannins and related phenolic substances which show virucidal effects in several viral systems. Lithospermic acid (**Figure [1](#F1){ref-type="fig"}**) isolated from *Salvia miltiorrhiza* has strong anti-HIV activity in H9 cells ([@B1]). Punicalagin, chebulagic acid, and punicalin are hydrolysable tannins that demonstrate anti-HIV activity and come from *Terminalia chebula* ([@B88]). Repandusinic acid has shown inhibition of HIV-1 RTase and is extracted from *Phyllanthus niruri* of the Euphorbiaceae family ([@B116]). Monopotassium and monosodium salts of isomeric caffeic acid tetramer have shown inhibition of HIV replication and are obtained from the aqueous acetone extract of *Arnebia euchroma* of the Boraginaceae family ([@B67]). *Camellia*-tannin H shows inhibition of the HIV-1 protease and is extracted from the pericarp of *Camellia japonica* ([@B42]). Galloyl glucoses and gallic acid exhibited a hindrance of HIV integrase and are extracted from *Terminalia chebula* of the Combretaceae family ([@B3]; [@B120]). Mallotojaponin is a dimeric phloroglucinol derivative that inhibits activity of HIV-1 RTase and is extracted from the pericarps of *Mallotus japonicus*. The curcuminoids have shown inhibition of HIV-1 and HIV-2 protease and are extracted from rhizomes of *Curcuma longa* ([@B132]). Peltatol A is a prenylated catechol dimer that shows anti-HIV activity and is extracted from *Pothomorphe peltata* of the Piperaceae family ([@B54]).

Lignans
-------

Several lignans have antiviral properties ([@B20]). Phyllamyricin B and its lactone retrojusticidin B display inhibition of HIV-RTase activity and are obtained from chloroform extract of *Phyllanthus myrtifolius*/*P. urinaria* of the Euphorbiaceae famly ([@B91]). Anolignan B, anolignan A, and dibenzylbutadiene lignans have shown inhibition of HIV-1 RTase and are extracted from *Anogeissus acuminata* ([@B129]). Gomisin has been found to be one of the strongest inhibitors of HIV replication and is obtained from *Kadsura interior* ([@B22]).

Quinones
--------

Plumbagin, 1,4-naphthoquinone, juglone, and vitamin K3 are naphthoquinones that all demonstrate HIV inhibitory activity ([@B105]). Conocurvone is a trimeric naphthoquinone that shows effective anti-HIV activity and is extracted from *Conospermum incurvum* of the Proteaceae family ([@B30]).

Saponins
--------

Actein is a tetracyclic triterpenoid saponin that exhibits strong anti-HIV activity and derives from the rhizome of *Cimicifuga racemosa* (black cohosh), ([@B138]).

Xanthones
---------

Swertifrancheside is a flavonone--xanthone glucoside that has shown inhibition of HIV-1 RTase and is extracted from *Swertia franchetiana* ([@B168]). Macluraxanthone B is a prenylated xanthone that also shows anti-HIV activity and is extracted from *Maclura tinctoria* of the Moraceae family ([@B53]).

**Table [1](#T1){ref-type="table"}** list the ongoing or completed clinical trials of anti-HIV effect of natural substances.

###### 

Summary of clinical trials of natural products for treating HIV and AIDS.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Natural product and Country                                                                            Design                                                                                 Aim                                                                                                                                                                                       Treatment plan                                                                                                                                                                                                                                                                                                             Study phase and Reference
  ------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------
  *Echinacea purpurea*- Spain                                                                            Non-Randomized, Single Group Assignment two arms, Open Label trial                     To characterize drug interactions between medicinal herb *Echinacea purpurea* widely used by HIV infected patients and its interaction with protease inhibitor Darunavir/Ritonavir        Recruiting 15 HIV-1 infected patients on antiretroviral therapy with darunavir/ritonavir 600/100 mg twice a day for 4 weeks. Treating these patients with *Echinacea purpurea* for 14 days, 500 mg every 6 h.                                                                                                              Phase 4 ([@B108])

  *Echinacea purpurea*- Spain                                                                            Non-Randomized, Single Group Assignment two arms, Open Label trial                     To characterize drug interactions between one medicinal herb: *Echinacea purpurea* and the protease inhibitor etravirine                                                                  Recruiting 15 HIV-infected patients on stable antiretroviral therapy including etravirine at the dosage of 200 mg twice daily during at least 4 weeks. Treating these patients with *Echinacea purpurea* root (500 mg every 8 h) in addition to their antiretroviral treatment, from day 1 until 2 weeks later (day 14).   Phase 1 ([@B43])

  *Triptolide woldifiion*- China                                                                         Randomized, Factorial Assignment, two arms,\                                           To evaluate the effects and side effects of ARV treatment in acute HIV-1 infection phase, and to evaluate the impact of Triptolide wilfordii on HIV-1 reservoir                           Recruiting 18 naive-treatment patients with acute HIV-1 infection phase, and treating with the antiretroviral drugs (Tenofovir plus lamivudine plus Lopinavir/ritonavir plus raltegravir). Six months later, treating these 12 patients with Triplitode.                                                                   Phase 3 ([@B87])
                                                                                                         Open Label trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  *Triptolide wilfordii*- China                                                                          Randomized, Crossover Assignment two arms,\                                            To evaluate impact of Triptolide wilfordii on T-cell immune activation and inflammation biomarkers in HIV-infected immunological non-responders                                           Recruiting 120 patients from 4 HIV/AIDS clinical centers and treating the invention group with *Triptolide wilfordii* (20 mg tid po) for 24 weeks.                                                                                                                                                                         Phase 1 ([@B93])\
                                                                                                         Double Blind, placebo-controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Phase 2

  *Tripterygium wilfordii* Hook F (TwHF)- China                                                          Parallel, Non-Randomized, two arms, open label trial                                   Safety and Efficacy Study of *Tripterygium wilfordii* Hook F Extract in cART-Treated HIV Patients With Poor Immune Responses                                                              Recruiting 23 patients immunological non-responders, 19 receive TwHF extract (10 mg tid po) plus current cART, while four patients continue their current cART for 12 months.                                                                                                                                              ([@B111]; [@B124])

  *Moringa oleifera*- Zimbabwe                                                                           Observational, Case-Crossover, Prospective study                                       To study the effect of simultaneous treatment with antiretroviral drugs (nevirapine and efavirenz) and the herb Moringa                                                                   Recruiting 19 HIV-positive patients to compare the steady-state pharmacokinetics of nevirapine and efavirenz before and after supplementation with *Moringa oleifera* leaf powder.                                                                                                                                         ([@B146])

  Immunity 1 (Fuzheng 1)- China                                                                          Multi-center, Randomized, two arms, Double-blind, Placebo-controlled Clinical Trials   Study the effect of Immunity 1 (Fuzheng 1) on Immune Reconstitution of HIV Patients                                                                                                       Recruiting 60 HIV-positive patients (WHO clinical stage I and II) and treating with Fuzheng 1 (8.75 g twice a day) half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.                                                                                                      ([@B165])

  Immunity 1 and 3 (Fuzheng 1 and 3): Composed of herbs which have tonic and detoxific function- China   Multi-center, Randomized, three arms, Double Blind, placebo-controlled trial           To evaluate the efficacy and safety of combination of Traditional Chinese Medicine (TCM) and Highly Active Antiretroviral Therapy (HAART) on immune reconstitution of HIV/AIDS patients   Recruiting 180 HIV infected patients and treating with Fuzheng 1 or 3 (8.75 g/twice a day) half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.                                                                                                                              ([@B167])

  Immunity 2 (Fuzheng 2)- China                                                                          Parallel, randomized, two arms, Double Blind, placebo-controlled trial                 To evaluate the effect of immune 2 (Fuzheng 2) on immune reconstitution of adult HIV/AIDS patients who have received HAART                                                                Recruiting 180 HIV infected patients and treating with Fuzheng 2 (6.25 g twice a day) half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.                                                                                                                                   ([@B166])
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Ameliorating Effects of *Withania somnifera* (Ashwagandha) Root Extract on HIV-Associated Neurocognitive Disorders
------------------------------------------------------------------------------------------------------------------

It is well known that use of alcohol and drugs of abuse are associated with increased risk of attaining HIV-1 infection as well as augmented disease progression ([@B113], [@B112]; [@B34]; [@B11]). Further, studies have shown that use of alcohol and drugs of abuse are also risk factors for dementia and other cognitive disorders ([@B15]; [@B28]; [@B10]; [@B60]; [@B133]; [@B137]; [@B139],[@B140]). Along this line, impacting more than 15 million people worldwide, Alzheimer's disease (AD) is the most frequent form of senile dementia ([@B73]). This number will surely increase quickly in the future with augmented life expectancy. The pathological hallmarks of AD are complex and include neuronal degeneration, neuro-inflammation, toxic β-amyloid (AB) plaques, abnormal neurofibrillary tangles, and a decline of neurochemicals which are essential for neuronal transmission ([@B99], [@B101]; [@B130]; [@B55], [@B56]). The precise mechanisms of β-amyloid that lead to neurotoxicity continue to be a question but its cytotoxicity to neuronal cells has been acknowledged as one of the main features in AD pathology ([@B135]). In AB-induced cytotoxicity it seems that some of the possible mechanisms involved are oxidative stress and free radical formation ([@B177]). In HIV infection, neuronal degeneration is also a main feature. In AIDS patients, a noteworthy increase in brain APP has been observed especially in the axons found in the subcortical white matter tracts ([@B38]; [@B51]; [@B5]; [@B90]). HIV can persist in the brain during HAART therapy and local inflammatory responses can cause an increase of APP production and exposure to amyloid deposition ([@B6]). During HIV induced neuronal degeneration and development of Alzheimer's disease, β- amyloid buildup may be used as an indicator of early neuronal degeneration.

A medicinal plant that has many therapeutic properties such as antioxidant and immunomodulatory properties, memory enhancer, nerve tonic and antistress is *Withania somnifera* (L.) Dunal, also known as 'ashwagandha' (ASH) or 'Indian ginseng' and has had a significant upsurge in pharmacological studies in the recent years ([@B106]; [@B79]). In cultured neurons and in rodents injected with Aβ 25--35, neurite outgrowth has been induced by withanoside IV and withanolide A extracted from the roots ([@B78]). Root extracts from this species have also been shown to significantly reduce the number of hippocampal degenerating cells in the brains of stressed rodents ([@B66]) and were neuro-protective in animal models of Parkinson's disease ([@B142]). Accumulation of oligomers and β-amyloid peptides (Aβ), behavioral deficits and plaque pathology have been upturned in the brains of old and middle-aged APP/PS1 Alzheimer's disease transgenic mice with the oral dispensation of a semi-purified extract of the root of *W. somnifera* mainly involving withanosides and withanolides ([@B147]). However, there is a scarcity of data on the mechanisms related to the possible defensive effects of *W. somnifera* root against HIV-1Ba-L (clade B) infection and β-amyloid (1--42)-induced cytotoxicity. In a confocal microscopic analysis, β-amyloid treated SK-N-MC cells (neuronal cell line) showed a reduction in spine area, dendrite diameter, spine density, total dendrite, and a loss of spines when compared to untreated cells ([@B81]). Nonetheless, the toxic effects were counteracted when ASH root extract was added to β-amyloid treated cells ([@B81]). Further, as demonstrated by increased trypan blue stained cells, β-amyloid prompted cytotoxic effects in SK-N-MC cells. Nevertheless, the toxic effects were neutralized when ASH root extract was added to β-amyloid treated cells (**Figure [3](#F3){ref-type="fig"}**), ([@B82]). This observation was supported by the levels of acetylcholinesterase activity, cellular localization of β-amyloid, and MTT formazan exocytosis, confirming the defensive effects of ASH root extract against β-amyloid prompted toxicity ([@B81], [@B82]). Also, Withanolide A (WA; **Figure [2](#F2){ref-type="fig"}**) demonstrated the same pattern using MTT assay as a parameter and is a refined component of ASH (**Figure [4](#F4){ref-type="fig"}**) ([@B82]). These observations suggests that neuroprotective properties of ASH root extract may offer some clarification for the ethnopharmacological usages of ASH in traditional medicine for cognitive and other HIV associated neurodegenerative disorders and additionally ASH could be a possible new drug to reduce the brain amyloid load and/or improve the HIV-1 associated neurocognitive damages.

![**Effect of ASH in reversal of β-Amyloid induced cell death.** Treating the SK-N-MC cells with β-Amyloid **(B)** resulted in significant cell death when compared to the untreated control cells **(A)**. Treating the cells with ASH **(C)** and ASH plus β-Amyloid **(D)** exhibited good viability as evidenced by exclusion of trypan blue dye. \[Reproduced with permission from ([@B82]).\]](fmicb-06-01444-g003){#F3}

![**Effect of Withanolide A on viability of SK-N-MC cells treated with HIV-1Ba-L (clade B), Cocaine and Methamphetamine (METH): SK-N-MC cells were infected with HIV in the presence of Cocaine/METH.** The MTT assay is showing that Withanolide A reverse the neurotoxic effects on cell viability induced by HIV, Cocaine, METH and combined treatment. Withanolide A alone showed significant increase in cell viability. The values were expressed as percentage of cell viability compared to control cells and are the mean ± SD of four experiments. ^∗∗∗^, ^∗∗^, ^∗^ indicates a statistically significant difference (*p*,0.0001), (*p*,0.0006), and (*p*,0.0185), respectively, compared to controls. WA, Withanolide A; CO, COC, Cocaine; METH, Methamphetamine. \[Reproduced with permission from [@B82].\]](fmicb-06-01444-g004){#F4}

Apart from our studies on ASH, reports are scanty on the effect of natural compounds for the treatment of HIV associated neurocognitive disorders. *Ginkgo biloba* has been known as a traditional medicine for people with dementia. [@B184] reported that administration of EGb 761, a standardized formulation of *Ginkgo biloba* extract, reported to protect Tat transgenic mice from Tat-induced neuro toxic effects like developmental retardation, inflammation, death, astrocytosis, and neuron loss by down-regulating the glial fibrillary acidic protein (GFAP) expression. In GFAP null Tat-transgenic mice model, reduced Tat-induced neuropathological phenotypes including macrophage/microglia activation, central nervous system infiltration of T lymphocytes, and oxidative has been reported.

*Hypericum perforatum* (St John's Wort) extracts are generally used for the treatment of mild to moderately severe depression. Role of P27^SJ^~,~ a protein present in a laboratory callus culture of *Hypericum perforatum* was explored to control HIV transcription and replication in microglia and astrocytes ([@B27]). This study reported that P27^SJ^ suppress transcription of the HIV-1 Genome/viral replication (50%) by interacting, inhibiting the DNA-binding activity and altering subcellular localization of CCAAT/enhancer-binding protein beta (C/EBPb), a transcription factor that regulates expression of the HIV-1 genome. Also, P27^SJ^ reported to interact with HIV-1 Tat and inhibits its activity on transcription of HIV-1 LTR and relocalizing it to the cytoplasm. Therefore P27^SJ^ is a potential therapeutic agent for inhibiting the HIV-1 induced neurotoxicity in the brain by suppressing its replication and inhibiting inflammatory response induced by proinflammatory Tat-inducible chemokines such as MCP-1. Few studies reported the potential adverse St. John's Wort extracts drug reactions and interactions especially with other antidepressants, with coumarin-type anticoagulants, the immunosuppressants cyclosporine and tacrolimus, protease and RT inhibitors used in anti-HIV treatment ([@B145]).

For inhibiting the HIV replication in the brain or nullifying the neurotoxicity induced by HIV replication and its proteins, further studies are necessary to explore the neuroprotective effect of natural compounds like Sage (*Salvia officinalis, Salvia lavandulaefolia, Salvia lavandulifolia*), Bacopa (*Bacopa monnieri*), Gotu kola (*Centella asiatica*), which are being used as a therapeutic alternative medicines for memory and cognitive improvement.

Plant Compounds Taking Action on Viral Marks and Advantages
===========================================================

In the study of plant extracted anti-HIV compounds there have been significant improvements that are centered on their activity *in vitro* and the mechanisms that are used. Some of these compounds will be discussed in this review along with the viral targets they interact with. Covering all the natural substances that possess these anti-HIV properties is still a work in progress. Most of these compounds interfere with early steps in the HIV replication, such as the virus entry steps and on the viral enzymes RT and integrase.

Virus Entry
-----------

Many protein interactions are involved in HIV entry and have the potential to become targets for the development of new entry blockers. The HIV fusion inhibitor, Enfuvirtide ([@B65]) does not have oral bioavailability but requires two injections per day and can cause significant local side effects. Compounds that are recognized as strong inhibitors of HIV-1 and HIV-2 replication *in vitro* are sulfated polysaccharides ([@B171]; [@B94]). These compounds exert their anti-HIV properties by shielding off the positively charged amino acids in the V3 loop of the glycoprotein gp120 from the viral envelope of HIV ([@B171]). The V3 loop is necessary for virus attachment to cell surface heparan sulfate, a primary binding site, before more specific binding occurs to the CD4 receptor of CD4^+^ cells. Ursolic acid, oleanolic acid, betulinic acid and their derivatives have been the focus of recent research on triterpenoids. Inhibition of HIV-1 protease has been observed *in vitro* with these triterpenes. One of the many betulinic acid derivatives that were synthesized in a structure-activity relationship study, RPR103611, was chosen for additional mechanistic research. Numerous important steps of the HIV life cycle have been inhibited by flavonoids. Viral protease has been inhibited by taxifolin which is a flavanone with an OH group at position C-3′. Aromadendrin does not inhibit viral protease or RT but can inhibit interactions between CD4 and gp120, is more definite in its antiviral activity and is a flavanone that lacks an OH group at position C-3′ ([@B95]). The (-)-epigallocatechin 3-*O*-gallate has demonstrated activity against HIV-1 ([@B29]) such as a damaging effect of virus particles and post-adsorption entry and inhibition of RT and viral protease ([@B179]). Flavonoids are recognized as inhibitors of several enzymes including RT which is crucial for HIV replication ([@B74]) viral protease ([@B175]) and integrase ([@B72]).

Reverse Transcription
---------------------

The viral reproductive cycle begins when the enzymes within the nucleoprotein complex are activated after the virus enters the cell. The viral RT transcribes the RNA genome of HIV into a double-stranded DNA form after the nucleoprotein core of the virus is disrupted. RNA reverse transcription to DNA, degradation of RNA template by RN-ase H and duplication of the remaining DNA strand are the three consecutive functions that are controlled by the HIV-1- RT. The 4-propyldipyranocoumarins or calanolides are natural products that have been considered to be potential anti-HIV agents. (+)-Calanolide A ([@B18]) is significantly more active on inhibition of HIV-1 RT when compared to cordatolides A ([@B65]) and B ([@B94]). Currently, to evaluate its pharmacokinetics and safety, (+)-calanolide A is being tested in clinical trials for both HIV-infected and healthy volunteers ([@B26]).

Integration
-----------

Besides protease and RT, integrase is the only enzyme that is encoded by HIV-1. Strand transfer and 3′-processing are the two steps for integration of viral DNA into host DNA and are catalyzed by integrase. This enzyme first cleaves the last two nucleotides from each 3′-end of the linear viral DNA. Then the nucleophilic attack of these 3′-ends on host chromosomal DNA are involved in the subsequent DNA strand transfer reaction. The l-chicoric acid was the most active inhibitor of HIV integrase out of all the bis-catechols tested. Recently, due to its compelling anti-HIV potential, MAP30 received a lot of attention and is a plant protein of 30 kDa extracted from Momordica charantia L., ([@B85]; [@B152]). Moreover, this plant protein toxicity is definite to HIV-infected cells, does not exhibit opposing effects on normal cells and is an inhibitor of HIV-1 integrase by rendering the HIV LTR an unsuitable substrate for HIV integrase as well as DNA gyrase.

Transcription
-------------

Until levels of its trans-activator protein Tat rise, HIV-1 DNA transcription is low after integration of viral DNA into the host genome. By binding to the transactivation response element (TAR) at the 5′-end of the viral mRNA, Tat, an 86-amino acid polypeptide, can increase the capacity of host RNA polymerase ([@B125]). The transcriptional activity of HIV-1 long terminal repeat (LTR) can be stimulated by the Tat protein after being released from HIV-1-infected cells and has entered new cells in an active form ([@B97]). Between positions 133 and 104 of the HIV promoter, tannic acid has been observed to have found a putative tannic acid-responsive element and suppress 12-*O*-tetradecanoylphorbol 13-acetate (TPA) -- inducing HIV promoter activity ([@B156]). Furthermore, a number of natural substances related to tannins were assessed for their HIV promoter repression effects ([@B155]). Chalcones, 3-phenylcoumarins and isoflavones have all successfully repressed TPA-induced HIV promoter activity in a structure-activity relationship study.

Conclusion
==========

Although, antiretroviral drugs can bring about the repression of the serum load of the virus to undetectable levels, economical, commercial, and political barriers have limited their accessibility to a good part of the population suffering from the diseases. Natural products, particularly those in traditional medicine have supplied a basis of new drug candidates for many diseases including HIV and other neurocognitive disorders. The number of compounds exhibiting anti-HIV activity isolated from plants is increasing gradually and due to their explicit activity, there are several natural products have been used as primary compounds. Since the resistance of HIV-1 to the antiretroviral drugs has been increasing along with the necessity of agents that are not as costly and toxic as the ones being used now, new treatments with these natural products are needed. The basic challenge that still persists is to develop viral replication-targeted therapy using novel anti-HIV compounds with new mode of action, accepted toxicity, and less resistance profile. Against this backdrop, the World Health Organization (WHO) suggested the need to evaluate ethno-medicines for the management of HIV/AIDS. Accordingly, there is need to evaluate traditional medicine, particularly medicinal plants and other natural products that may yield effective and affordable therapeutic agents ([@B174]; [@B64]; [@B57]). In this context, the above mentioned results demonstrate that several plants, the majority of which are usually utilized for the treatment of various illnesses, are active against HIV. Since they are the indicators for the decision making at various levels and the finding of new lead substances, these reports are invaluable. The preparation, cytotoxicity, or selectivity profile of an antiviral substance should also be carefully assessed before any further attention is given to it. However, in repressing HIV progression and replication it should be stressed that several natural products primarily extracted from plants have demonstrated to be effective. HIV/AIDS being an exceptional epidemic, demands an exceptional approach and that forms very much our current and future research.
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